# Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

Source: https://onco.cc/trials/nct05485766/  
OnCo record `nct05485766` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of pembrolizumab, paclitaxel / nab-paclitaxel, carboplatin and olaparib in triple-negative breast cancer, run by Okayama University, now recruiting.

## Summary

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer is a phase 2, interventional study registered as NCT05485766 by Okayama University, with a registry enrolment figure of 23 participants, started 2024-07-16 and due to reach its primary completion in 2028-06-30. Interventions recorded: Pembrolizumab; Paclitaxel; Carboplatin; Olaparib; Definitive Surgery. Conditions listed: Triple Negative Breast Neoplasms; Triple Negative Breast Cancer; Breast Neoplasms; Breast Cancer; BRCA1 Mutation; BRCA2 Mutation; BRCA Mutation; BRCA-Associated Breast Carcinoma. Triple-negative eligibility wording from the registry: "* Have histologically confirmed TNBC, as defined by the most recent ASCO/CAP guidelines". Sites: Japan. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT05485766
- Phase: 2
- Setting: Neoadjuvant and Adjuvant Olaparib Plus Pembrolizumab Following Platinum Based Chemotherapy Plus Pembrolizumab for Germline BRCA Mutated Triple Negative Breast Cancer (WJOG14020B/OPERETTA)
- Sponsor: Okayama University
- Enrolled: 23

## Sources

- ClinicalTrials.gov NCT05485766: https://clinicaltrials.gov/study/NCT05485766

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [PARP inhibitors](https://onco.cc/technologies/parp-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Olaparib](https://onco.cc/drugs/olaparib/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05485766.json